STXS
Stereotaxis Inc

2,010
Mkt Cap
$281.41M
Volume
0.00
52W High
$3.59
52W Low
$1.54
PE Ratio
-10.91
STXS Fundamentals
50D MA
$2.95
Beta
0.98
Avg. Volume
412,106.71
EPS (Annual)
-$0.2976
P/B
182.52
Rev/Employee
$193,654.68
Loading...
Loading...
News
all
press releases
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
Zacks·5d ago
News Placeholder
More News
News Placeholder
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.
Zacks·10d ago
News Placeholder
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Zacks·1mo ago
News Placeholder
STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep
Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.
Zacks·2mo ago
News Placeholder
ISRG's SP Stapler: A Game Changer for Colorectal and Thoracic Procedures?
Intuitive Surgical's new SP stapler opens doors to colorectal and thoracic surgeries, potentially transforming the single-port platform's adoption curve.
Zacks·2mo ago
News Placeholder
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +28.57% and +10.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know
Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Teleflex (TFX) Q2 Earnings and Revenues Top Estimates
Teleflex (TFX) delivered earnings and revenue surprises of +11.01% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Zacks·4mo ago
News Placeholder
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago

Latest STXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.